Julie I. Krystal

Julie I. Krystal

Pediatric Hematology Oncology | Pediatrics | Oncology

269-01 76th Avenue
Suite 255
New Hyde Park, NY 11040

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Correction: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Journal: Frontiers in oncology

Published: May 20, 2026

"No meat no treat" Comment on: 18F-FDG PET/CT in pediatric langerhans cell histiocytosis: Relation to BRAFv600e mutation and risk stratification.

"No meat no treat" Comment on: 18F-FDG PET/CT in pediatric langerhans cell histiocytosis: Relation to BRAFv600e mutation and risk stratification.

Journal: European journal of radiology

Published: May 13, 2026

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

Journal: Clinical pharmacokinetics

Published: February 05, 2026

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors.

Journal: Frontiers in oncology

Published: August 05, 2025

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.

Journal: Pediatric blood & cancer

Published: November 21, 2024

Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.

Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 30, 2023

A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas.

A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas.

Journal: Pediatric blood & cancer

Published: August 18, 2023

Treatment of High-Risk Neuroblastoma.

Treatment of High-Risk Neuroblastoma.

Journal: Children (Basel, Switzerland)

Published: June 08, 2023

Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.

Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.

Journal: Neuro-oncology

Published: April 09, 2022

New pediatric leukemia/lymphoma diagnoses during the COVID-19 pandemic: A New York perspective.

New pediatric leukemia/lymphoma diagnoses during the COVID-19 pandemic: A New York perspective.

Journal: Pediatric blood & cancer

Published: February 09, 2022

Successful use of crushed formulation of dabrafenib and trametinib in a pediatric glioneural tumor.

Successful use of crushed formulation of dabrafenib and trametinib in a pediatric glioneural tumor.

Journal: Pediatric blood & cancer

Published: May 28, 2021

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.

Journal: Cancer medicine

Published: August 19, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026